Zentalis Reports Presentation Of Positive Phase 1b Data Demonstrating Durable Responses And Favorable Safety Profile Of Azenosertib In Combination With Chemotherapy At 2023 ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Zentalis Pharmaceuticals reported positive Phase 1b data for azenosertib in combination with chemotherapy at the 2023 ASCO Annual Meeting. The results showed strong anti-tumor activity in platinum-resistant ovarian cancer patients. Zentalis plans to initiate a Phase 3 trial in Q1 2024.
May 25, 2023 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zentalis Pharmaceuticals reported positive Phase 1b data for azenosertib, showing strong anti-tumor activity in ovarian cancer patients. The company plans to initiate a Phase 3 trial in Q1 2024.
The positive Phase 1b data for azenosertib demonstrates its potential in treating platinum-resistant ovarian cancer patients. This news is likely to have a positive impact on Zentalis' stock price as it shows progress in the company's drug development pipeline and plans to initiate a Phase 3 trial in Q1 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100